• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

Traditional treatment and medications don't work for a majority of people suffering from depression. The individual approach to treatment could be the answer.

Cue is an intervention platform for digital devices that converts passively collected sensor data from smartphones into customized micro-interventions designed to improve mental health. We analyzed the most effective-fit personal ML models for each subject using Shapley values to discover their feature predictors and reveal distinct features that deterministically change mood with time.

Predictors of Mood

Depression is a leading cause of mental illness in the world.1 Yet only half of those suffering from the condition receive home treatment for depression. In order to improve outcomes, clinicians need to be able to recognize and treat patients who have the highest probability of responding to specific treatments.

Personalized depression treatment is one method to achieve this. By using sensors on mobile phones as well as an artificial intelligence voice assistant, and other digital tools, researchers at the University of Illinois Chicago (UIC) are working on new ways to determine which patients will benefit from which treatments. Two grants worth more than $10 million will be used to discover biological and behavior predictors of response.

To date, the majority of research into predictors of depression treatment effectiveness has been focused on clinical and sociodemographic characteristics. These include demographic variables like age, sex and educational level, clinical characteristics like symptom severity and comorbidities, and biological markers like neuroimaging and genetic variation.

While many of these factors can be predicted by the information available in medical records, only a few studies have used longitudinal data to explore predictors of mood in individuals. Few studies also consider the fact that mood can vary significantly between individuals. Therefore, it is crucial to develop methods that permit the determination and quantification of the individual differences in mood predictors treatments, mood predictors, etc.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. The team can then develop algorithms to recognize patterns of behaviour and emotions that are unique to each individual.

The team also created a machine-learning algorithm that can create dynamic predictors for each person's mood for depression. The algorithm combines these personal characteristics into a distinctive "digital phenotype" for each participant.

This digital phenotype was associated with CAT DI scores, a psychometrically validated symptom severity scale. The correlation was not strong however (Pearson r = 0,08; BH adjusted P-value 3.55 10 03) and varied significantly between individuals.

Predictors of Symptoms

dementia depression treatment is one of the leading causes of disability1 yet it is often underdiagnosed and undertreated2. Depression disorders are rarely treated because of the stigma attached to them, as well as the lack of effective interventions.

To facilitate personalized home treatment for depression to improve treatment, identifying the patterns that can predict symptoms is essential. The current prediction methods rely heavily on clinical interviews, which are unreliable and only reveal a few characteristics that are associated with depression.

Machine learning can enhance the accuracy of diagnosis and treatment for depression by combining continuous, digital behavioral phenotypes collected from smartphone sensors along with a verified mental health tracker online (the Computerized Adaptive Testing Depression Inventory CAT-DI). These digital phenotypes allow continuous, high-resolution measurements and capture a wide range of unique behaviors and activity patterns that are difficult to capture through interviews.

The study comprised University of California Los Angeles students who had mild to severe depression symptoms who were enrolled in the Screening and Treatment for Anxiety and Depression program29 developed as part of the UCLA Depression Grand Challenge. Participants were sent online for support or clinical care according to the degree of their depression. Participants who scored a high on the CAT DI of 35 65 were assigned online support with an online peer coach, whereas those with a score of 75 were routed to in-person clinical care for psychotherapy.

At the beginning of the interview, participants were asked a series of questions about their personal characteristics and psychosocial traits. The questions included age, sex, and education and financial status, marital status as well as whether they divorced or not, their current suicidal thoughts, intent or attempts, as well as how often they drank. Participants also rated their degree of depression severity on a 0-100 scale using the CAT-DI. CAT-DI assessments were conducted every other week for the participants that received online support, and every week for those who received in-person treatment.

Predictors of the Reaction to Treatment

Research is focused on individualized depression treatment. Many studies are aimed at finding predictors, which can help clinicians identify the most effective drugs to treat each patient. Particularly, pharmacogenetics is able to identify genetic variants that influence how the body's metabolism reacts to antidepressants. This allows doctors select medications that are most likely to work for every patient, minimizing the amount of time and effort required for trial-and error treatments and avoid any negative side negative effects.

Another promising method is to construct models of prediction using a variety of data sources, including clinical information and neural imaging data. These models can be used to determine which variables are most likely to predict a specific outcome, like whether a medication can improve mood or symptoms. These models can also be used to predict the response of a patient to treatment that is already in place, allowing doctors to maximize the effectiveness of current therapy.

A new generation of studies uses machine learning methods like supervised learning and classification algorithms (like regularized logistic regression or tree-based methods) to combine the effects of multiple variables to improve predictive accuracy. These models have been demonstrated to be useful in predicting treatment outcomes for example, the response to antidepressants. These approaches are becoming more popular in psychiatry and could become the standard of future treatment.

In addition to the ML-based prediction models research into the mechanisms behind postpartum depression natural treatment continues. Recent research suggests that the disorder is linked with neural dysfunctions that affect specific circuits. This theory suggests that an individualized treatment for depression will be based upon targeted therapies that restore normal function to these circuits.

One way to do this is by using internet-based programs which can offer an individualized and tailored experience for patients. One study found that an internet-based program improved symptoms and provided a better quality life for MDD patients. A randomized controlled study of an individualized treatment for depression found that a significant percentage of participants experienced sustained improvement as well as fewer side effects.

Predictors of Side Effects

In the treatment of depression, one of the most difficult aspects is predicting and determining which antidepressant medications will have minimal or zero adverse negative effects. Many patients are prescribed a variety of drugs before they find a drug that is safe and effective. Pharmacogenetics offers a new and exciting method of selecting antidepressant medications that is more effective and specific.

There are several predictors that can be used to determine which antidepressant should be prescribed, such as gene variations, patient phenotypes such as gender or ethnicity, and co-morbidities. However, identifying the most reliable and reliable predictive factors for a specific treatment will probably require randomized controlled trials of considerably larger samples than those normally enrolled in clinical trials. This is due to the fact that it can be more difficult to identify moderators or interactions in trials that only include one episode per participant rather than multiple episodes over time.

In addition the prediction of a patient's response will likely require information on the severity of symptoms, comorbidities and the patient's personal perception of the effectiveness and tolerability. Currently, only some easily identifiable sociodemographic and clinical variables seem to be reliably associated with response to MDD factors, including gender, age race/ethnicity, BMI and the presence of alexithymia and the severity of depressive symptoms.

The application of pharmacogenetics in treatment for depression is in its early stages and there are many obstacles to overcome. It is crucial to have a clear understanding and definition of the genetic mechanisms that cause depression, as well as a clear definition of an accurate predictor of treatment response. Ethics such as privacy and the responsible use of genetic information are also important to consider. In the long term the use of pharmacogenetics could offer a chance to lessen the stigma associated with mental health treatment and improve the treatment outcomes for patients with depression. But, like all approaches to psychiatry, careful consideration and implementation is essential. The best course of action is to provide patients with an array of effective depression medication options and encourage them to speak with their physicians about their experiences and concerns.